AVTX Stock Analysis: Buy, Sell, or Hold?
AVTX - Avalo Therapeutics, Inc. Common Stock
$21.57
-1.30 (-5.68%)
▼
5d:
+57.33%
30d:
+51.79%
90d:
+52.01%
WAIT
LOW Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 11, 2026
TODAY
Smart Money Accumulation
AVTX is down 4.6% this week, but smart money is accumulating calls. Top strike: $15 2026-06-18 with 2,939 OI. Call ratio: 100% View Scanner →
Strength: 7.3/10
Get Alerted When AVTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called AVTX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: AVTX is 20.8% above its trading range ($17.85). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: AVTX is 20.8% above its trading range ($17.85). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: AVTX is currently trading at $21.57, which is considered extended relative to its 30-day fair value range of $12.72 to $17.85.
Technical Outlook: Technically, AVTX is in a downtrend. Immediate support is located at $12.51, while resistance sits at $24.27. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: AVTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $40.09 (+85.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AVTX is in a downtrend. Immediate support is located at $12.51, while resistance sits at $24.27. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: AVTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $40.09 (+85.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$12.72 -
$17.85
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.4%
All Signals
- BEARISH: Price significantly overextended (+20.8% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.7%)
- BULLISH: Trading 85.9% below Wall St target ($40.09)
- WARNING: Recommendation downgraded due to 20.8% overvaluation
Trading Range Analysis
30-Day Trading Range
$12.72 -
$17.85
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$12.51
Resistance Level
$24.27
Current Trend
Downtrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.25
Wall Street Target
$40.09
(+85.9%)
Revenue Growth (YoY)
-69.3%
Share & Embed Analysis
Last updated: May 10, 2026 9:17 AM ET
Data refreshes hourly during market hours. Next update: 10:17 AM
Data refreshes hourly during market hours. Next update: 10:17 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AVTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Mittie Doyle
SELL
3970 shares
2026-04-06
Christopher Ryan Sullivan
SELL
7980 shares
2026-04-02
Christopher Ryan Sullivan
SELL
7979 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$23 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$208 | 46 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 60 HOLD |
